Dr Greg Collier

ChemGenex Subsidiary Receives US Therapeutic Discovery Grant

ChemGenex Announces Convertible Note Issue and Welcomes Cephalon, Inc. as a Substantial Investor

ChemGenex has signed a convertible note deal giving Cephalon up to A$15 million in notes, plus options over 19.9 percent of shares held by Stragen and Merck; major shareholders back the issue.

Also GBS Ventures

ChemGenex CEO Receives AusBiotech Award

AusBiotech's release announces ChemGenex chief executive Greg Collier won the 2009 Chairman's Excellence Award for his contribution to Australian biotechnology, noting the company's US drug application for a leukemia medicine.

ChemGenex Appoints Mr. Thomas DeZao as Senior Vice President and

ChemGenex Pharmaceuticals has hired Thomas DeZao as senior vice president and chief commercial officer to lead US commercialisation of its leukemia drug omacetaxine; his past roles span Genitope, Corixa/Coulter, Asta Medica and Chiron.

ChemGenex to Seek Voluntary De-listing from NASDAQ and to Restructure Board to

ASX-listed drug developer ChemGenex will quit NASDAQ and SEC reporting to cut compliance costs, and three directors step down in July while staying on as advisers.

ChemGenex's Omacetaxine Kills Leukemic Stem Cells in Human CML Models

ChemGenex Pharmaceuticals reports pre-clinical findings that omacetaxine destroys leukemic stem cells in chronic myeloid leukemia models, presented at the European Hematology Association congress, with collaborators in Glasgow and a US leukemia specialist.

Pivotal Study Results: ChemGenex's Omacetaxine May Provide the First Viable Drug

ChemGenex reported Phase 2/3 trial results for omacetaxine in resistant CML patients at ASCO, with investigators suggesting it could become the first workable therapy for T315I-mutant patients; regulatory filing targeted for Q3.

ChemGenex Appoints Experienced Biotechnology Executive as Chief Medical Officer

ChemGenex Pharmaceuticals has hired oncology drug developer Dr Adam Craig as its chief medical officer, its third senior clinical appointment lately, as it prepares its cancer drug omacetaxine for a regulatory filing.

ChemGenex Appoints Dr George Morstyn to Board of Directors

A 2007 announcement that Australian biotech ChemGenex Pharmaceuticals appointed former Amgen executive Dr George Morstyn to its board, with CEO Greg Collier citing his oncology development and commercialisation expertise.

ChemGenex Announces Initiation of Second Phase 2/3 Clinical Trial for Ceflatoninr in CML

ChemGenex has begun enrolling patients in a second phase 2/3 trial testing Ceflatonin in chronic myeloid leukemia patients resistant to prior tyrosine kinase inhibitor treatment, with data expected in 2008.

ChemGenex Announces the Completion of A$21 Million Financing

ChemGenex completed an A$10.5m rights issue following an equal February institutional placement, a combined A$21m raise, with Alta Partners and GBS Venture Partners increasing their stakes to fund Ceflatonin leukemia trials.